PROCR Antibody

What is PROCR and why are antibodies against it important in research?

PROCR (Protein C Receptor), also known as Endothelial Protein C Receptor (EPCR), is a transmembrane glycoprotein primarily expressed on endothelial cells that plays crucial roles in coagulation, inflammation, and cell signaling pathways. Antibodies against PROCR are essential research tools that enable detection, quantification, and functional analysis of this receptor in various experimental settings. These antibodies facilitate investigation of PROCR's role in thrombosis, sepsis, cancer progression, and other pathological conditions. The importance of PROCR antibodies has grown significantly as researchers have discovered the receptor's involvement in diverse cellular processes beyond its canonical role in the protein C anticoagulant pathway. When selecting a PROCR antibody, researchers should consider the specific experimental application (immunohistochemistry, flow cytometry, western blotting, etc.) and ensure the antibody has been validated for that particular technique .

How can I verify the specificity of a PROCR antibody?

Verifying antibody specificity is critical to ensure experimental reproducibility and valid research findings. According to the International Working Group for Antibody Validation established in 2016, there are five key pillars for confirming antibody specificity :

• Genetic strategies: Compare binding signals between cells expressing PROCR and those with PROCR knocked out using CRISPR or RNAi techniques. A specific antibody will show no binding in PROCR-negative cells. While RNAi can suppress protein expression, its transient nature makes CRISPR-based validation more reliable for complete knockouts .

• Orthogonal strategies: Correlate antibody-based detection with an antibody-independent method like mass spectrometry or mRNA quantification to confirm that protein levels match across different detection methods.

• Independent antibody strategies: Verify results using multiple antibodies targeting different epitopes of PROCR, which should yield consistent results if they are all specific.

• Expression of tagged proteins: Compare antibody detection with detection of an epitope-tagged version of PROCR to confirm concordant signals.

• Immunocapture followed by mass spectrometry: Use the antibody to immunoprecipitate PROCR and then analyze the captured proteins by mass spectrometry to confirm specific binding.

Implementing at least one of these validation approaches is essential before using a PROCR antibody in critical experiments. Thorough validation increases research quality and reproducibility by ensuring that observed signals truly represent PROCR rather than cross-reactive proteins .

How should I properly cite and document the PROCR antibody used in my research?

Proper citation of antibodies is crucial for research reproducibility. The Antibody Registry provides Research Resource Identifiers (RRIDs) that serve as persistent identifiers for antibodies used in research. When documenting a PROCR antibody, include the following information in your methods section: commercial source, catalog number, clone name (for monoclonal antibodies), lot number (if relevant for polyclonal antibodies), and the RRID when available . For example: "Anti-PROCR monoclonal antibody (Vendor X, Cat# ABC123, RRID:AB_123456) was used at 1:1000 dilution for western blotting." The RRID allows other researchers to unambiguously identify the exact antibody used, even if it is later discontinued or the vendor changes. Many journals now require or strongly encourage the use of RRIDs in publications, with journals actively requiring antibody RRIDs showing over 90% compliance while those with passive instructions showing only about 1% compliance . Including this detailed information helps address the reproducibility crisis in biomedical research by enabling others to use identical reagents when attempting to replicate your findings.

What strategies can improve PROCR antibody specificity for detecting low-abundance targets?

Detecting low-abundance PROCR, particularly in tissues where expression is minimal, requires optimized strategies to enhance specificity and sensitivity. First, consider signal amplification methods such as tyramide signal amplification (TSA) or polymer-based detection systems, which can significantly increase detection sensitivity without compromising specificity. Second, implement rigorous blocking protocols using both protein blockers (BSA, normal serum) and specific blockers for endogenous peroxidases, biotin, and Fc receptors to minimize background signal that can mask low-level PROCR detection . Third, employ antigen retrieval optimization specific to PROCR's structural characteristics - testing both heat-induced epitope retrieval (HIER) at various pH conditions and enzymatic retrieval methods to maximize epitope accessibility while preserving tissue morphology. Fourth, consider using highly sensitive detection systems like quantum dots or fluorescent nanoparticles which offer superior signal-to-noise ratios compared to conventional chromogens. Finally, validate all optimizations using appropriate positive and negative controls, including tissues with known PROCR expression levels and genetic knockout samples where available . These comprehensive approaches can significantly enhance the detection of low-abundance PROCR while maintaining the specificity necessary for accurate experimental outcomes.

How can I design experiments to investigate PROCR antibody cross-reactivity in multi-species studies?

Designing robust experiments to evaluate cross-reactivity of PROCR antibodies across species requires a systematic approach. Begin with sequence homology analysis comparing PROCR amino acid sequences from target species to identify conserved and variable regions, particularly focusing on the epitope recognized by your antibody if this information is available. Prepare a validation panel consisting of recombinant PROCR proteins from each species of interest and related proteins with similar structural domains to test for both species cross-reactivity and off-target binding . Implement western blot analysis using tissue lysates from multiple species, running them in parallel under identical conditions to directly compare binding patterns and molecular weights. For immunohistochemistry applications, create a tissue microarray containing PROCR-expressing tissues from all relevant species, processed and stained simultaneously to control for technical variables . Additionally, perform flow cytometry on cells expressing PROCR from different species, quantifying binding affinity differences. For definitive validation, conduct immunoprecipitation coupled with mass spectrometry on samples from each species to confirm the identity of pulled-down proteins. Document all findings in a comprehensive cross-reactivity matrix that details binding characteristics across species and techniques, which will serve as an essential reference for your research and potential publication .

How can I apply AI technologies to optimize PROCR antibody generation and screening?

Artificial intelligence is revolutionizing antibody research, including PROCR antibody development. Advanced AI algorithms can analyze massive antibody-antigen interaction datasets to predict optimal antibody structures against specific PROCR epitopes. The Vanderbilt University Medical Center team, awarded $30 million from ARPA-H, is developing such AI technologies to address traditional antibody discovery bottlenecks like inefficiency, high costs, and poor scalability . To implement AI in your PROCR antibody research, start by creating comprehensive training datasets that include successful and failed PROCR antibody sequences along with their binding properties. Utilize machine learning models like deep neural networks to predict antibody-PROCR binding affinities and structural complementarity. These models can identify optimal complementarity-determining regions (CDRs) and framework modifications to enhance specificity and affinity . For screening applications, integrate high-throughput experimental data with AI analysis pipelines to rapidly identify promising candidates and predict their performance across different experimental conditions. Collaborative approaches combining computational expertise with immunology knowledge yield the best results. This AI-driven methodology represents a significant advancement over traditional antibody discovery approaches, potentially reducing development time from years to months while increasing success rates and antibody performance characteristics .

What are the optimal conditions for PROCR antibody validation in different experimental applications?

Optimal PROCR antibody validation requires application-specific approaches to ensure reliability across different experimental techniques. For western blotting, validate under both reducing and non-reducing conditions since PROCR's conformation may affect epitope accessibility. Optimize protein loading (10-50 μg), blocking agents (5% BSA often outperforms milk for phospho-specific detection), and exposure times while including positive controls (recombinant PROCR) and negative controls (PROCR-knockout samples) . For immunohistochemistry/immunofluorescence, test multiple fixation methods (4% paraformaldehyde, acetone, methanol) as they significantly impact epitope preservation. Perform titration experiments (typically 1:100 to 1:2000 dilutions) and optimize antigen retrieval conditions (citrate buffer pH 6.0 or EDTA pH 9.0) while including appropriate tissue controls . For flow cytometry, optimize antibody concentration, incubation time/temperature, and buffer composition while validating with fluorescence-minus-one (FMO) controls and isotype controls. For immunoprecipitation, test different lysis buffers (RIPA, NP-40, digitonin) as detergent strength affects PROCR solubilization and antibody accessibility. For all applications, perform application-specific knockout validations following the "genetic strategy" pillar of antibody validation . Document all optimization parameters in standardized validation reports, including controls used, experimental conditions, and quantitative specificity metrics. This systematic approach ensures that PROCR antibody performance is optimized for each specific application, enhancing experimental reliability and reproducibility.

What are the best methodologies for using PROCR antibodies in multiplex immunostaining applications?

Multiplex immunostaining with PROCR antibodies requires careful planning and optimization to achieve reliable results. Begin by selecting compatible antibodies raised in different host species (e.g., rabbit anti-PROCR paired with mouse antibodies against other targets) to avoid cross-reactivity between secondary antibodies. If antibodies from the same species are necessary, use sequential immunostaining with complete stripping or blocking of the first primary-secondary antibody complex before applying subsequent antibodies . For fluorescent multiplex applications, select fluorophores with minimal spectral overlap and implement proper controls including single-stained samples to establish compensation parameters. Tyramide signal amplification (TSA) can significantly enhance detection sensitivity while allowing antibody stripping between rounds, enabling the use of multiple same-species antibodies . For chromogenic multiplex assays, optimize the order of detection based on antigen abundance (detecting less abundant targets first) and use specialized multiplex detection kits that produce distinct chromogens at different cellular locations. Validate the multiplex protocol by comparing staining patterns with those observed in single-staining experiments to ensure antibody performance isn't compromised. When designing panels that include PROCR, consider its co-localization patterns with other proteins of interest and select markers that provide meaningful biological context, such as endothelial markers (CD31), coagulation factors, or inflammatory mediators depending on your research question . Finally, implement automated image analysis with appropriate algorithms to quantify co-localization and expression levels, reducing subjective interpretation and enhancing reproducibility.

How should researchers design experiments using PROCR antibodies in antibody-drug conjugate (ADC) development?

Designing experiments for PROCR antibody-drug conjugate development requires a systematic approach using Design of Experiments (DOE) methodology. First, establish analytical methods that can accurately characterize ADC attributes including drug-antibody ratio (DAR), aggregation propensity, and binding affinity to PROCR . Start with a factorial design to explore critical process parameters that affect PROCR ADC quality. Based on standard ADC development experience, key factors typically include protein concentration (5-15 mg/mL), conjugation temperature (16-26°C), buffer pH (6.8-7.8), and reaction time (60-180 minutes) . Set specific quality attribute targets, such as a DAR range of 3.4-4.4 with an optimal target of 3.9, to evaluate experimental outcomes. Use statistical software like MODDE to create your experimental design and analyze results to identify significant parameters and interactions . For optimal scale-down model development, ensure your laboratory-scale experiments accurately represent manufacturing conditions by maintaining consistent mixing parameters, concentration gradients, and surface-to-volume ratios. Implement in-process analytical techniques to monitor conjugation kinetics and stability during development. Use orthogonal analytical methods for comprehensive ADC characterization, including hydrophobic interaction chromatography (HIC) for DAR analysis, size exclusion chromatography (SEC) for aggregation assessment, and cell-based assays to confirm retained PROCR binding specificity and potency post-conjugation . Finally, develop a robust control strategy based on your identified critical parameters to ensure consistent manufacturing of PROCR ADCs with predefined quality attributes.

How can researchers address discrepancies in PROCR detection across different antibody-based techniques?

Addressing discrepancies in PROCR detection across different techniques requires systematic investigation of technique-specific factors. First, document all discrepancies precisely, noting which techniques show inconsistent results (e.g., positive western blot but negative immunohistochemistry). Consider epitope accessibility variations - certain techniques denature proteins (western blot) while others require native conformation (flow cytometry), which may explain why some antibodies work in one application but not another . Evaluate fixation and processing effects, particularly for tissue-based assays, as overfixation can mask epitopes while inadequate fixation may lose antigens. Implement epitope mapping to identify exactly which region of PROCR your antibody recognizes, helping explain technique-specific variations. For quantitative discrepancies, develop standard curves using recombinant PROCR for each technique to normalize signals across methods . Consider post-translational modifications like glycosylation which may affect antibody binding differently across techniques - PROCR is known to be heavily glycosylated, which can obscure epitopes in certain contexts. Perform side-by-side analysis of the same samples using multiple detection antibodies that recognize different PROCR epitopes. Additionally, complement antibody-based methods with antibody-independent techniques like mass spectrometry or PCR to resolve contradictions . Finally, consult the Antibody Registry and published literature for reports of similar discrepancies, as other researchers may have already identified and resolved the same issues with particular PROCR antibodies .

What statistical approaches are recommended for analyzing variability in PROCR antibody performance across different lots?

Managing antibody lot-to-lot variability requires robust statistical approaches to ensure experimental reliability. Begin by implementing a routine quality control program where each new PROCR antibody lot is tested alongside the previous lot using identical samples and protocols. Collect quantitative data including signal intensity, background levels, and specific-to-nonspecific signal ratios. For statistical analysis, employ paired t-tests or Wilcoxon signed-rank tests to compare performance metrics between lots, establishing whether differences exceed acceptable thresholds . Calculate the coefficient of variation (CV) both within and between lots; generally, intra-lot CV should be <10% and inter-lot CV <20% for acceptable reproducibility. For more comprehensive analysis, use two-way ANOVA to simultaneously assess lot effects and sample effects while identifying potential interactions. Implement Bland-Altman plots to visualize agreement between lots across the entire dynamic range of PROCR detection. For critical assays, consider statistical equivalence testing rather than difference testing to define acceptable equivalence margins based on your experimental requirements . Maintain detailed records of lot-specific performance characteristics in a database that tracks trends over time. When significant lot differences are detected, perform additional validation using the five pillars approach to ensure specificity is maintained . Implement statistical process control charts to monitor antibody performance trends over time, enabling early detection of drift before it impacts experimental outcomes. These statistical approaches provide a quantitative framework for managing PROCR antibody variability and maintaining consistent experimental conditions despite inherent lot-to-lot differences.

How can researchers interpret complex datasets incorporating PROCR antibody staining with genomic and proteomic data?

Integrating PROCR antibody data with genomic and proteomic datasets requires sophisticated multi-omics analysis approaches. Begin by normalizing antibody-based quantification data against appropriate housekeeping controls to account for technical variations across samples. When correlating PROCR protein expression with transcriptomic data, implement time-lag analysis to account for the biological delay between mRNA expression and protein production, typically using Pearson or Spearman correlation with time-shift parameters. For spatial data integration, register antibody-based tissue imaging with spatial transcriptomics using landmark-based algorithms to precisely map PROCR protein localization to corresponding gene expression patterns . Employ machine learning approaches such as random forest or support vector machines to identify multi-omics signatures that predict PROCR functional states more accurately than single-dataset analyses. Calculate protein-mRNA correlation coefficients specifically for PROCR across your sample set to determine whether post-transcriptional regulation mechanisms are active. For pathway analysis, use specialized multi-omics integration tools like mixOmics or MOFA (Multi-Omics Factor Analysis) to identify co-regulated networks where PROCR participates . Visualize complex relationships using dimensionality reduction techniques including t-SNE or UMAP, color-coding points based on PROCR antibody intensity to identify expression patterns within multi-omics clusters. For validation, perform targeted experiments testing specific hypotheses generated from your integrated analysis, such as knockdown studies of transcription factors predicted to regulate PROCR. This methodical integration approach enables researchers to build comprehensive biological models of PROCR function that leverage the strengths of each data type while compensating for individual limitations.